Rose-tinted glasses might not save Genkyotex

Rose-tinted glasses might not save Genkyotex

Source: 
EP Vantage
snippet: 

Genkyotex wants to become a liver disease player, and it won’t let a detail like a trial failure put a brake on its ambitions. The company’s GKT831 has flunked a mid-stage study in its lead indication, primary biliary cholangitis, but Genkyotex claims to have seen enough to push on into phase III.